Cargando…

Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic

The global spread of COVID-19 constitutes the most dangerous pandemic to emerge during the last one hundred years. About seventy-nine million infections and more than 1.7 million death have been reported to date, along with destruction of the global economy. With the uncertainty evolved by alarming...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ruixuan, Stephen, Preyesh, Tao, Yi, Zhang, Wenfa, Lin, Sheng-Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Masson SAS. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834004/
https://www.ncbi.nlm.nih.gov/pubmed/33486202
http://dx.doi.org/10.1016/j.biopha.2021.111232
_version_ 1783642188355207168
author Wang, Ruixuan
Stephen, Preyesh
Tao, Yi
Zhang, Wenfa
Lin, Sheng-Xiang
author_facet Wang, Ruixuan
Stephen, Preyesh
Tao, Yi
Zhang, Wenfa
Lin, Sheng-Xiang
author_sort Wang, Ruixuan
collection PubMed
description The global spread of COVID-19 constitutes the most dangerous pandemic to emerge during the last one hundred years. About seventy-nine million infections and more than 1.7 million death have been reported to date, along with destruction of the global economy. With the uncertainty evolved by alarming level of genome mutations, coupled with likelihood of generating only a short lived immune response by the vaccine injections, the identification of antiviral drugs for direct therapy is the need of the hour. Strategies to inhibit virus infection and replication focus on targets such as the spike protein and non-structural proteins including the highly conserved RNA-dependent-RNA-polymerase, nucleotidyl-transferases, main protease and papain-like proteases. There is also an indirect option to target the host cell recognition systems such as angiotensin-converting enzyme 2 (ACE2), transmembrane protease, serine 2, host cell expressed CD147, and the host furin. A drug search strategy consensus in tandem with analysis of currently available information is extremely important for the rapid identification of anti-viral. An unprecedented display of cooperation among the scientific community regarding SARS-CoV-2 research has resulted in the accumulation of an enormous amount of literature that requires curation. Drug repurposing and drug combinations have drawn tremendous attention for rapid therapeutic application, while high throughput screening and virtual searches support de novo drug identification. Here, we examine how certain approved drugs targeting different viruses can play a role in combating this new virus and analyze how they demonstrate efficacy under clinical assessment. Suggestions on repurposing and de novo strategies are proposed to facilitate the fight against the COVID-19 pandemic.
format Online
Article
Text
id pubmed-7834004
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-78340042021-01-26 Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic Wang, Ruixuan Stephen, Preyesh Tao, Yi Zhang, Wenfa Lin, Sheng-Xiang Biomed Pharmacother Review The global spread of COVID-19 constitutes the most dangerous pandemic to emerge during the last one hundred years. About seventy-nine million infections and more than 1.7 million death have been reported to date, along with destruction of the global economy. With the uncertainty evolved by alarming level of genome mutations, coupled with likelihood of generating only a short lived immune response by the vaccine injections, the identification of antiviral drugs for direct therapy is the need of the hour. Strategies to inhibit virus infection and replication focus on targets such as the spike protein and non-structural proteins including the highly conserved RNA-dependent-RNA-polymerase, nucleotidyl-transferases, main protease and papain-like proteases. There is also an indirect option to target the host cell recognition systems such as angiotensin-converting enzyme 2 (ACE2), transmembrane protease, serine 2, host cell expressed CD147, and the host furin. A drug search strategy consensus in tandem with analysis of currently available information is extremely important for the rapid identification of anti-viral. An unprecedented display of cooperation among the scientific community regarding SARS-CoV-2 research has resulted in the accumulation of an enormous amount of literature that requires curation. Drug repurposing and drug combinations have drawn tremendous attention for rapid therapeutic application, while high throughput screening and virtual searches support de novo drug identification. Here, we examine how certain approved drugs targeting different viruses can play a role in combating this new virus and analyze how they demonstrate efficacy under clinical assessment. Suggestions on repurposing and de novo strategies are proposed to facilitate the fight against the COVID-19 pandemic. Published by Elsevier Masson SAS. 2021-05 2021-01-13 /pmc/articles/PMC7834004/ /pubmed/33486202 http://dx.doi.org/10.1016/j.biopha.2021.111232 Text en © 2021 Published by Elsevier Masson SAS. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Wang, Ruixuan
Stephen, Preyesh
Tao, Yi
Zhang, Wenfa
Lin, Sheng-Xiang
Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic
title Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic
title_full Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic
title_fullStr Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic
title_full_unstemmed Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic
title_short Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic
title_sort human endeavor for anti-sars-cov-2 pharmacotherapy: a major strategy to fight the pandemic
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834004/
https://www.ncbi.nlm.nih.gov/pubmed/33486202
http://dx.doi.org/10.1016/j.biopha.2021.111232
work_keys_str_mv AT wangruixuan humanendeavorforantisarscov2pharmacotherapyamajorstrategytofightthepandemic
AT stephenpreyesh humanendeavorforantisarscov2pharmacotherapyamajorstrategytofightthepandemic
AT taoyi humanendeavorforantisarscov2pharmacotherapyamajorstrategytofightthepandemic
AT zhangwenfa humanendeavorforantisarscov2pharmacotherapyamajorstrategytofightthepandemic
AT linshengxiang humanendeavorforantisarscov2pharmacotherapyamajorstrategytofightthepandemic